Bupropion SR for the Treatment of Substance- Abusing Outpatient Adolescents with Attention- Deficit/Hyperactivity Disorder and Mood Disorders
| Autor: | Joseph Biederman, Stephanie L. Van Patten, Timothy E. Wilens, Jefferson B. Prince, Ramon Solhkhah, Jeanine Daly |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Substance-Related Disorders behavioral disciplines and activities mental disorders medicine Humans Attention deficit hyperactivity disorder Pharmacology (medical) Child Psychiatry Bupropion Retrospective Studies Mood Disorders Hamilton Rating Scale for Depression medicine.disease Substance abuse Psychiatry and Mental health Mood Mood disorders Attention Deficit Disorder with Hyperactivity Delayed-Action Preparations Pediatrics Perinatology and Child Health Clinical Global Impression Anxiety Female Bupropion hydrochloride medicine.symptom Psychology Clinical psychology |
| Zdroj: | Journal of Child and Adolescent Psychopharmacology. 15:777-786 |
| ISSN: | 1557-8992 1044-5463 |
| DOI: | 10.1089/cap.2005.15.777 |
| Popis: | Few studies exist on pharmacological interventions for adolescents with substance use disorders (SUD). To this end, we evaluated the response of bupropion hydrochloride sustained release (SR) in SUD adolescents with comorbid psychopathology (both attention-deficit/ hyperactivity disorder (ADHD) and a mood disorder).Fourteen adolescent outpatients were treated naturalistically and followed openly for 6 months. Adolescents were rated using the Drug Use Screening Inventory--Revised (DUSI-R), ADHD Symptom Checklist, and the Hamilton Rating Scale for Depression (HAM-D). Clinical Global Impression (CGI) Scale scores were obtained for Substance Abuse, ADHD, Anxiety, and Depression. The ratings were completed at baseline, at month 3, and at the 6-month endpoint. Bupropion SR was initiated at 100 mg once-daily and titrated naturalistically to a maximum dose of 400 mg/day.Of the 14 subjects followed, 13 subjects completed 6 months of treatment. At the 6- month endpoint compared to baseline, treatment with bupropion was associated with clinical and significant reductions in DUSI scores (-39%; p0.05), ADHD symptom checklist (-43%; p0.001), HAM-D (-76%; por = 0.001); and reductions in the CGIs for ADHD (por = 0.001), depression (por = 0.001), and substance abuse (p0.05). The mean daily dose of bupropion SR was 315 mg (in divided doses). No significant adverse events were noted during the follow-up period.These naturalistic data suggest that bupropion is well tolerated and may be an effective medication for the treatment of substance abusing adolescents with comorbid mood disorders and ADHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|